Regeneron Reports Q4 Earnings; Analysts Respond Mixed

Regeneron Pharmaceuticals shares have lagged behind the market, with a Q4 EPS of $12.07 and revenues of $3.8 billion. Analysts maintain a mixed outlook, suggesting possible fluctuations in stock prices due to varying EPS projections.

Date: 25-02-2025

AI Rating: 5

Earnings Per Share (EPS)
Regeneron's Q4 EPS of $12.07 was better than expected, indicating strong performance in the past quarter. However, analysts project a decline of nearly 7% in EPS for the current fiscal year, totaling $35.92, which might signal challenges ahead for the company.

Revenue Growth
Q4 revenue reached $3.8 billion, a 10% year-over-year increase. This growth indicates a solid demand for Regeneron’s products, particularly driven by strong sales of Libtayo and collaboration revenues with Sanofi.

Net Income
The report indicates a 1.8% year-over-year net income growth, which, while positive, is modest compared to the revenue growth. This could suggest pressures on profitability that may arise from various operational factors.

Profit Margins
There is no specific data provided in terms of gross, operating, or net profit margins in this report. Thus, we cannot assess the company's profitability with detail.

Free Cash Flow (FCF)
No information regarding free cash flow was mentioned in the report. Understanding this metric could have provided additional insights on Regeneron's liquidity and financial health.

Return on Equity (ROE)
No ROE data was available in the text, therefore this analysis cannot determine the efficiency of Regeneron in generating profit from its equity.

Overall, the mixed ratings from analysts, including a “Strong Buy” consensus from most while some continue to show caution with an “Underperform” rating, suggest that investor sentiment may influence stock prices significantly. As REGN struggles against the broader market performance—and with expectations of declining EPS—investors should tread carefully as they assess potential risks and rewards of investing in Regeneron.

Stocks: REGN